Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Tacrolimus in Primary Membranous Nephropathy
NCT04629248Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of obinutuzumab in primary membranous nephropathy (PMN), sponsored by Roche. Started Jun 2021; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
primary membranous nephropathy (PMN)
Beyond the preview
Go deeper on NCT04629248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629248.